Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide as Adjunct to Insulin in Type 1 Diabetes
NCT01836523Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2013
- Primary completion
- Jun 2015
- Modality
- Peptides
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Change From Baseline in HbA1c (Glycosylated Haemoglobin) at 52 weeks, Change From Baseline in Body Weight at 52 weeks and 1 more. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01836523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836523.